Department of Infectious Diseases, Affiliated Hospital of Weifang Medical University, Weifang 261031, Shandong, China.
Imaging Center, Affiliated Hospital of Weifang Medical University, Weifang 261031, Shandong, Chin.
Acta Biochim Pol. 2021 May 19;68(2):293-300. doi: 10.18388/abp.2020_5569.
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. This study aimed to analyze the prognostic value of microRNA-1266-5p (miR-1266-5p) in HCC patients and investigate its biological function in HCC progression.
The expression of miR-1266-5p in tissues and cells was measured by quantitative real-time PCR (qRT-PCR). Cell counting kit-8 (CCK-8) assay was used to detect HCC cell proliferation. Transwell assay was performed to evaluate the migration and invasion of HCC cells. Kaplan-Meier methods and Cox regression analysis were used to assess the prognostic value of miR-1266-5p in HCC patients. The relationship between miR-1266-5p and DAB2IP was evaluated by luciferase reporter assay.
Relative expression of miR-1266-5p in tumor tissues, tissues from patients with advanced TNM stage (III-IV) and HCC cells was increased compared with that in corresponding control group. MiR-1266-5p expression was significantly associated with tumor size and TNM stage in HCC patients. Elevated expression of miR-1266-5p was associated with poor prognosis of HCC patients and served as an independent prognostic factor for HCC patients. Overexpression of miR-1266-5p significantly promoted, while miR-1266-5p knockdown significantly inhibited the proliferation, migration and invasion of HCC cells. DAB2IP could directly bind to the miR-1266-5p.
Our findings indicated that elevated expression of miR-1266-5p can predict the poor prognosis of HCC patients, and promotes the proliferation, migration and invasion of HCC cells. Therefore, we predict that miR-1266-5p may be a novel biomarker and therapeutic target for the treatment of HCC.
肝细胞癌(HCC)是全球癌症相关死亡的主要原因之一。本研究旨在分析 microRNA-1266-5p(miR-1266-5p)在 HCC 患者中的预后价值,并研究其在 HCC 进展中的生物学功能。
采用实时定量 PCR(qRT-PCR)检测 miR-1266-5p 在组织和细胞中的表达。细胞计数试剂盒-8(CCK-8)检测 HCC 细胞增殖。Transwell 检测 HCC 细胞迁移和侵袭。Kaplan-Meier 法和 Cox 回归分析评估 miR-1266-5p 对 HCC 患者的预后价值。荧光素酶报告实验评估 miR-1266-5p 与 DAB2IP 的关系。
与相应对照组相比,肿瘤组织、晚期 TNM 分期(III-IV 期)患者组织和 HCC 细胞中的 miR-1266-5p 相对表达增加。miR-1266-5p 表达与 HCC 患者的肿瘤大小和 TNM 分期显著相关。miR-1266-5p 高表达与 HCC 患者的不良预后相关,是 HCC 患者的独立预后因素。miR-1266-5p 过表达显著促进 HCC 细胞的增殖、迁移和侵袭,而 miR-1266-5p 敲低则显著抑制 HCC 细胞的增殖、迁移和侵袭。DAB2IP 可直接与 miR-1266-5p 结合。
我们的研究结果表明,miR-1266-5p 表达升高可预测 HCC 患者的不良预后,并促进 HCC 细胞的增殖、迁移和侵袭。因此,我们预测 miR-1266-5p 可能是 HCC 治疗的新型生物标志物和治疗靶点。